Related references
Note: Only part of the references are listed.Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
Eric A. F. Simoes et al.
LANCET CHILD & ADOLESCENT HEALTH (2023)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis
You Li et al.
LANCET (2022)
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
Lisa M. DeTora et al.
ANNALS OF INTERNAL MEDICINE (2022)
Antibody Responses to Respiratory Syncytial Virus: A Cross-Sectional Serosurveillance Study in the Dutch Population Focusing on Infants Younger Than 2 Years
Guy Berbers et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali
Andrea G. Buchwald et al.
CLINICAL INFECTIOUS DISEASES (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins
Rutger M. Schepp et al.
MSPHERE (2019)
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
Joseph B. Domachowske et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study
Jacqueline U. McDonald et al.
VACCINE (2018)
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
M. Pamela Griffin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya
Joyce U. Nyiro et al.
PLOS ONE (2017)
Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay
Cindy Shambaugh et al.
CLINICAL AND VACCINE IMMUNOLOGY (2017)
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses
Concepcion Palomo et al.
JOURNAL OF VIROLOGY (2016)
Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus
Sarah V. Maifeld et al.
PLOS ONE (2016)
Novel antigens for RSV vaccines
Barney S. Graham et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Community-Acquired Pneumonia Requiring Hospitalization among US Adults
S. Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Joan O. Ngwuta et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya
Joyce U. Nyiro et al.
VACCINE (2015)
Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein
Sangeeta Kumari et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness
Ann R. Falsey et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh
Helen Y. Chu et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
Jason S. McLellan et al.
SCIENCE (2013)
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Margarita Magro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: Children and elderly
P. Sastre et al.
JOURNAL OF VIROLOGICAL METHODS (2010)
The Level and Duration of RSV-Specific Maternal IgG in Infants in Kilifi Kenya
Rachel Ochola et al.
PLOS ONE (2009)
The 24-angstrom structure of respiratory syncytial virus nucleocapsid protein-RNA decameric rings
Kirsty MacLellan et al.
JOURNAL OF VIROLOGY (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Seroprotection rate, mean fold increase, seroconversion rate:: which parameter adequately expresses seroresponse to influenza vaccination?
WEP Beyer et al.
VIRUS RESEARCH (2004)
A role for immune complexes in enhanced respiratory syncytial virus disease
FP Polack et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
